HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration

• Main Authors: Ying Lu (Author), Fan Shen (Author), Wen-Qiang He (Author), An-Qi Li (Author), Ming-Hua Li (Author), Xiao-Li Feng (Author), Yong-Tang Zheng (Author), Wei Pang (Author)
• Format: Book
• Published: Elsevier, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The continuously emerging SARS-CoV-2 variants pose a great challenge to the efficacy of current drugs, this necessitates the development of broad-spectrum antiviral drugs. In the previous study, we designed a recombinant protein, heptad repeat (HR) 121, as a variant-proof vaccine. Here, we found it...